|
| Aeolus Pharmaceuticals, Inc. | | | | Aeolus Pharmaceuticals, Inc., a biopharmaceutical company, engages in the development of a class of catalytic antioxidant compounds. It offers catalytic antioxidant compounds as a medical countermeasure against biological, chemical, and radiological weapons, as well as for diseases and disorders of the central nervous system, respiratory system, autoimmune system, and oncology. The company develops AEOL 10150, which completed two Phase I clinical trials for various indications, such as medical countermeasure against the effects of acute radiation syndrome in the lungs and gastro-intestinal tract; and as a countermeasure for exposure to chemical vesicants, including chlorine gas and sulfur mustard gas. It also has two programs for the development of AEOL 11207, a drug candidate for the potential treatment of epilepsy and Parkinson’s disease. The company was founded in 1994 and is based in Mission Viejo, California. | | | | Advanced Cell Technology, Inc. | | | | Advanced Cell Technology, Inc., a biotechnology company, focuses on the development and commercialization of human embryonic and adult stem cell technology in the field of regenerative medicine. Its embryonic stem cell research programs include cellular reprogramming, reduced complexity program, and stem cell differentiation research programs. The company’s cellular reprogramming involves in the development of therapies based on the use of genetically identical pluripotent stem cells generated by its cellular reprogramming technologies. Advanced Cell Technology, Inc. also generates stable cell lines with particular focus on blood lineage and vascular epithelial cell lines from hemangioblast cells. In addition, it is developing an autologous myoblast transplantation therapy to restore cardiac function in patients with advanced heart disease. The company’s stem cell-based therapy would provide treatment for a range of acute and chronic degenerative diseases. Further, it develops adult stem cell-based products that are specifically targeted at therapies for heart and other cardiovascular diseases. The company is headquartered in Marlborough, Massachusetts. | | | | Li3 Energy | | | | Li3 Energy, Inc. is a South American based global exploration and developmental stage public company in the lithium mining and energy sector. Li3 aims to acquire, develop and commercialize a significant portfolio of lithium brine deposits in the Americas. With its controlling interest in its Maricunga project (consisting of mining concessions covering an area of approximately 3,553 acres located in the Salar de Maricunga in northern Chile) and its other prospective strategic lithium and mineral holdings, Li3 Energy is focused on commercializing these assets in an accelerated manner by exploring the use of intensified evaporative and other advanced processing technologies. Li3's goals are to; a) support the global implementation of clean and green energy initiatives; b) meet growing lithium market demand and; c) become a mid-tier, low cost supplier of lithium, potassium nitrate, iodine and other strategic minerals, serving global clients in the energy, fertilizer and specialty chemical industries. Li3 is led by a management team of seasoned industry veterans with extensive exploration, mining, minerals, finance and commercialization expertise and a Board of Directors including global industry thought leaders who have advised, led and operated numerous mining entities. Additional information regarding the company can be found in our recent filings with the SEC as well as the information maintained on our website www.li3energy.com. | | |
|
|